Evidence map›Paper›PMID 25356347›Full record

ArticleNew microbes and new infections2014

Validation of a novel real-time PCR for detecting Rasamsonia argillacea species complex in respiratory secretions from cystic fibrosis patients.

J Steinmann, S Giraud, D Schmidt, L Sedlacek, A Hamprecht, J Houbraken, J F Meis, J P Bouchara, J Buer, P-M Rath

Abstract read
In one paragraph

Article in New microbes and new infections, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. DisseminatedMedical mycology case reports · 2024
    Article
  3. Article
  4. SystemicJMM case reports · 2017
    Article
  5. In Vitro Activity of Isavuconazole against Rasamsonia Species.Antimicrobial agents and chemotherapy · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

J SteinmannInstitute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen Essen, Germany.
S GiraudL'UNAM Université, Université d'Angers, Groupe d'Etude des Interactions Hôte-Pathogène Angers, France.
D SchmidtInstitute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen Essen, Germany.
L SedlacekInstitute of Medical Microbiology and Hospital Epidemiology, Hannover Medical School Hannover, Germany.
A HamprechtInstitute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne Cologne, Germany.
J HoubrakenCBS-KNAW Fungal Biodiversity Centre Utrecht, The Netherlands.
J F MeisDepartment of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital Nijmegen, The Netherlands ; Department of Medical Microbiology, Radboud University Medical Centre Nijmegen, The Netherlands.
J P BoucharaL'UNAM Université, Université d'Angers, Groupe d'Etude des Interactions Hôte-Pathogène Angers, France ; Laboratory of Parasitology and Mycology, Angers University Hospital Angers, France.
J BuerInstitute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen Essen, Germany.
P-M RathInstitute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Members of the recently introduced fungal genus Rasamsonia (formerly included in the Geosmithia genus) have been described as emerging pathogens in immunosuppressed hosts or patients with cystic fibrosis (CF). Rasamsonia species have often been misidentified as Penicillium or Paecilomyces because of similar morphological characteristics. We validated a commercially available real-time PCR assay (Primerdesign™, UK) for accurate detection of species from the Rasamsonia argillacea complex. First, we tested this assay with a collection of 74 reference strains and clinical isolates and then compared the PCR with cultures of 234 respiratory samples from 152 patients with CF from two University Hospitals in Germany and France. The assay reliably detected the three main species within the Rasamsonia argillacea species complex (R. argillacea, R. piperina, R. aegroticola), which are typically encountered in CF patients. The limit of DNA detection was between 0.01 and 1 pg/μL. Analysis of the DNA extracts from respiratory specimens of CF patients revealed that four out of the 153 patients studied (2.6%) were colonized with R. argillacea species complex. Two species from the R. argillacea complex grew in the parallel cultures from the same patients. In one patient the PCR was positive 5 months before culture. The real-time PCR assay is a sensitive and specific method for detecting the three most important species of the R. argillacea species complex encountered in the CF context. Detection of these emerging pathogens in respiratory secretions from CF patients by this novel assay may increase our understanding of the occurrence and epidemiology of the R. argillacea species complex.

Indexed as

Cystic fibrosisGeosmithiaPCRRasamsonia

Identifiers

PMID25356347
PMCPMC4184661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.